Results 21 to 30 of about 6,458 (228)
Tibial bypass salvage with eptifibatide in a patient with thrombocythemia [PDF]
Journal of Vascular Surgery Cases, 2015 Early graft failure is a complex and challenging clinical condition faced by vascular surgeons performing infrainguinal bypass surgery. This case describes a patient with undiagnosed thrombocytosis undergoing urgent open revascularization for critical limb ischemia.
John Byrne +4 more
openalex +4 more sources
Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage
Case Reports in Critical Care, 2021 Background. Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests antibody-dependent
Gregory Byrd +5 more
doaj +1 more source
In vitro and patient studies with platelets to explore off-target cardiovascular effects of integrase inhibitors. [PDF]
HIV MedAbstract Introduction People with HIV currently face a tenfold higher risk of developing cardiovascular disease (CVD) than those without HIV. Studies have shown various off‐target effects of antiretroviral treatment (ART) on the cardiovascular system, but little is known about the effects of currently used integrase strand transfer inhibitors (INSTIs ...
Keniyopoullos R +3 more
europepmc +2 more sources
Application of eptifibatide injection in acute ischemic cerebrovascular disease [PDF]
Xin yixue, 2022 Objective To evaluate the treatment effectiveness and safety of eptifibatide injection in the treatment of acute ischemic cerebrovascular disease （ICVD）.
Mei Ni, Tian Liang
doaj +1 more source
Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets [PDF]
Circulation, 2005 Background— Pretreatment is not the most common strategy practiced for clopidogrel administration in elective coronary stenting. Moreover, limited information is available on the antiplatelet pharmacodynamics of a 300-mg versus a 600-mg clopidogrel loading dose, and the comparative effect of ...
Paul A. Gurbel +5 more
openalex +4 more sources
Кардиоваскулярная терапия и профилактика, 2023 Aim. To study the safety and efficacy of Angipure in acute ST-segment elevation coronary syndrome (STE-ACS) and high-risk percutaneous transluminal coronary angioplasty (PTCA) compared with eptifibatide.Material and methods.
S. V. Lukyanov +6 more
doaj +1 more source
Safety of Eptifibatide for Subcortical Stroke Progression [PDF]
Cerebrovascular Diseases, 2009 <i>Background:</i> There is no proven treatment for stroke progression in patients with subcortical infarcts. Eptifibatide, a glycoprotein IIb/IIIa inhibitor, might halt stroke progression by improving flow in the microcirculation. <i>Methods:</i> We conducted a retrospective analysis of patients with subcortical stroke who ...
James C. Grotta +8 more
openaire +3 more sources
The Egyptian Heart Journal, 2023 Background ST-segment elevation myocardial infarction (STEMI) is usually caused by a rupture in the atherosclerotic plaque, followed by platelet aggregation which ultimately leads to acute coronary artery occlusion.
Rozita Jalalian +5 more
doaj +1 more source
Journal of Interventional Medicine, 2020 Objective: To compare the antiplatelet effect and major adverse cerebrovascular events of Pipeline for intracranial aneurysms using glycoprotein IIb/IIIa antagonists (GPI) eptifibatide and tirofiban.
Qiao Deng +4 more
doaj +1 more source
Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. [PDF]
, 2017 Acute ischemic stroke is a devastating cause of death and disability, consequences of which depend on the time from ischemia onset to treatment, the affected brain region, and its size.
Akyol, Onat +6 more
core +3 more sources